Swiss Real Estate Stock News

SWX:NESN
SWX:NESNFood

Nestlé Reshapes Portfolio As Ice Cream And Waters Sales Loom

Nestlé (SWX:NESN) is in advanced talks to sell its ice cream business as part of a CEO led turnaround plan. The company has also begun a sale process for its waters and drinks division, pointing to a potential exit from sizeable parts of its portfolio. These moves follow pressure on profits linked to baby formula recalls and increasing demands from shareholders for change. Nestlé is one of the largest global consumer packaged food companies, with brands across coffee, pet care,...
SWX:SFZN
SWX:SFZNLife Sciences

Assessing Siegfried Holding’s Valuation After Earnings Growth, Acquisitions And Governance Updates

Siegfried Holding (SWX:SFZN) has released its full year 2025 results, reporting CHF 1,327.83 million in sales and CHF 168.66 million in net income, along with management changes and updates on recent acquisitions. See our latest analysis for Siegfried Holding. The latest CHF80.7 share price leaves Siegfried Holding with a 90 day share price return of 12.4%, while the 1 year total shareholder return of 16.8% decline contrasts with a 24.2% gain over three years. This suggests that longer term...
SWX:ABBN
SWX:ABBNElectrical

How Investors May Respond To ABB (SWX:ABBN) Rising Robotics Demand And AI-Flagged Medium-Term Opportunities

Recently, ABB has seen elevated trading activity in pre-market sessions, supported by ongoing industrial demand and strong spending in robotics and electrification solutions. An interesting angle is that third-party AI-driven models are flagging medium-term growth opportunities for ABB, even as some valuation concerns remain. We’ll now examine how this renewed confidence in robotics and automation demand fits into, and potentially reshapes, ABB’s existing investment narrative. The future of...
SWX:TEMN
SWX:TEMNSoftware

A Look At Temenos’s (SWX:TEMN) Valuation As Mixed 2025 Earnings Prompt Investor Reassessment

Temenos (SWX:TEMN) is back in focus after reporting fourth quarter and full year 2025 results, with softer quarterly earnings but higher full year revenue and net income, prompting investors to reassess the stock. See our latest analysis for Temenos. Temenos shares trade at CHF64.2, with a 1 day share price return of 0.94% and a 7 day share price return of 1.82%. The 30 day share price return shows a 13.36% decline and the year to date share price return shows a 21.23% decline, while the 5...
SWX:AMRZ
SWX:AMRZBasic Materials

Is It Too Late To Consider Amrize (SWX:AMRZ) After The Recent Share Price Jump?

If you are wondering whether Amrize is priced fairly or if there could be value on the table, this article will walk through what the current share price might be telling you. Amrize shares last closed at CHF 50.14, with returns of 13.7% over the past week, 16.7% over the past month and 12.7% year to date, which may have changed how investors view its potential and its risks. Recent attention around Amrize has prompted fresh interest in how the company is being valued, with investors looking...
SWX:SIKA
SWX:SIKAChemicals

Sika’s Akkim Deal Tests Growth Story After Softer 2025 Results

Sika (SWX:SIKA) has agreed to acquire Turkey based adhesives and sealants manufacturer Akkim. The deal is part of Sika’s Strategy 2028 to expand its adhesives and sealants business globally. The planned transaction increases Sika’s production footprint and presence in high growth markets. Sika focuses on specialty chemicals for construction and industrial applications, and adhesives and sealants are a core part of that offering. By adding Akkim’s product range and manufacturing base in...
SWX:PGHN
SWX:PGHNCapital Markets

Is Partners Group Holding (SWX:PGHN) Now An Opportunity After Recent Share Price Weakness?

If you are wondering whether Partners Group Holding is currently offering fair value or a potential opportunity, looking closely at its valuation can help put the recent share price in context. The stock closed at CHF 852.60, with returns of 9.6% decline over 7 days, 20.2% decline over 30 days, 17.2% decline year to date, 33.2% decline over 1 year, 7% return over 3 years and 11.2% decline over 5 years. These moves may have changed how the market views its risk and potential. Recent coverage...
SWX:ROG
SWX:ROGPharmaceuticals

Assessing Roche Holding (SWX:ROG) Valuation After FDA Progress For Giredestrant And Genomics Tailwinds

FDA filing for breast cancer drug puts Roche Holding (SWX:ROG) in focus Roche Holding (SWX:ROG) is back on investors’ radar after the U.S. FDA accepted its New Drug Application for giredestrant in ER positive, HER2 negative, ESR1 mutated advanced breast cancer. The filing, supported by phase III evERA Breast Cancer data, comes alongside positive readouts for Gazyva in kidney disease and constructive industry views on next generation sequencing and genetic testing, areas where Roche is an...
SWX:NESN
SWX:NESNFood

Is Nestlé (SWX:NESN) Pricing Reflect Its Recent Multi‑Year Share Price Weakness

If you are wondering whether Nestlé shares still justify their price, you are not alone; the stock often attracts investors who care about what they are actually paying for each franc of underlying business. Nestlé shares last closed at CHF81.40, with returns of 1.5% over 7 days, 12.3% over 30 days, 6.5% year to date, and a 3.9% decline over 1 year, 17.8% decline over 3 years, and 3.3% decline over 5 years, hinting at changing views on its growth and risk profile. Recent headlines around...
SWX:COPN
SWX:COPNPharmaceuticals

Is Cosmo Pharmaceuticals (SWX:COPN) Still Attractive After 20% Pullback On 2025 Guidance?

If you are wondering whether Cosmo Pharmaceuticals at CHF116.20 is priced attractively or already baking in a lot of optimism, this article walks through what the numbers say about its value. The stock shows returns of 0.5% over 7 days, 1.8% over 30 days, 10.2% year to date, 76.5% over 1 year, 105.4% over 3 years and 53.4% over 5 years, which may prompt questions about how much of this performance is supported by fundamentals. Recent coverage has focused on Cosmo Pharmaceuticals' position...
SWX:AMRZ
SWX:AMRZBasic Materials

Amrize (SWX:AMRZ) Valuation Check After 2026 Guidance Dividends And Supportive Analyst Commentary

Amrize (SWX:AMRZ) has drawn fresh attention after issuing upbeat 2026 revenue guidance, outlining both ordinary and special dividend proposals, and attracting supportive analyst commentary following its recent spin off. See our latest analysis for Amrize. After the guidance, dividend proposals and recent board and auditor changes, Amrize’s 7 day share price return of 9.34% and 90 day share price return of 20.79% suggest building positive momentum from a starting point of CHF49.15. If this has...
SWX:PGHN
SWX:PGHNCapital Markets

Assessing Partners Group Holding (SWX:PGHN) Valuation After AI Infrastructure Shift And Record Fundraising Year

Event driven repositioning at Partners Group Holding Partners Group Holding (SWX:PGHN) is in focus after shifting capital away from technology and software toward AI linked infrastructure assets, while its open ended private credit funds avoided net redemptions during recent sector volatility. See our latest analysis for Partners Group Holding. The recent repositioning toward AI linked infrastructure comes after a mixed run for investors, with a 30 day share price return of 14.25% decline, a...
SWX:CMBN
SWX:CMBNConsumer Finance

How Investors Are Reacting To Cembra Money Bank (SWX:CMBN) Higher 2025 Net Income And Dividend

Cembra Money Bank AG has already reported its full-year 2025 results, with net interest income of CHF 372.16 million and net income of CHF 179.57 million, and announced an annual dividend of CHF 4.60 per share, ex-date April 28, 2026. While net interest income eased slightly from the prior year, higher net income and an increased dividend highlight the bank’s ability to convert its lending activities into growing shareholder distributions. Next, we’ll examine how the higher net income and...
SWX:SIKA
SWX:SIKAChemicals

Sika (SWX:SIKA) Net Margin Decline Tests Longstanding Profitability Narratives

Sika (SWX:SIKA) has wrapped up FY 2025 with Q4 revenue of CHF 2.6b and net income of CHF 174.1m, while Q4 basic EPS came in at CHF 1.09. Over the past few quarters, the company has reported revenue of CHF 2.8b and EPS of CHF 2.02 in Q4 2024, CHF 2.9b in Q3 2025, and CHF 2.6b in Q4 2025. This sets up a results season where investors are likely to focus on how these changes in revenue and EPS relate to margins. See our full analysis for Sika. With the latest figures on the table, the next step...
SWX:EFGN
SWX:EFGNCapital Markets

EFG International (SWX:EFGN) Margin Decline To 19.6% Tests Profitability Narrative

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...
SWX:COPN
SWX:COPNPharmaceuticals

Assessing Cosmo Pharmaceuticals (SWX:COPN) Valuation After Strong Revenue Update And Share Price Momentum

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...
SWX:BEKN
SWX:BEKNBanks

European Dividend Stocks With Up To 4.8% Yield

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.
SWX:ALC
SWX:ALCMedical Equipment

Is There Now An Opportunity In Alcon (SWX:ALC) After A 23.6% Share Price Drop

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...
SWX:BCVN
SWX:BCVNBanks

European Dividend Stocks To Consider In February 2026

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN): Are Renal Bets And Radiopharmaceuticals Quietly Reshaping Its Long-Term Growth Mix?

In early February 2026, Novartis reported final Phase III ALIGN data showing Vanrafia® (atrasentan) slowed kidney function decline in adults with IgA nephropathy, alongside a new long-term Actinium-225 supply agreement from Niowave to support its radioligand therapy portfolio for difficult-to-treat cancers. Together, these updates highlight Novartis’ effort to build depth in both renal disease and radiopharmaceutical oncology, reinforcing the importance of specialized therapies and secure...
SWX:SREN
SWX:SRENInsurance

3 European Dividend Stocks Yielding Up To 5.3%

As European markets navigate volatility, with the STOXX Europe 600 Index recently hitting a new high before settling nearly unchanged, investors are keenly observing economic indicators such as employment growth and GDP expansion in the eurozone. Amidst these dynamics, dividend stocks have gained attention for their potential to provide steady income; qualities like strong cash flow and a history of consistent payouts can make them appealing choices in uncertain market conditions.
SWX:LISN
SWX:LISNFood

Is Lindt’s DubaiStyle Expansion a Clue to Its Everyday Indulgence Strategy for (SWX:LISN) Investors?

In February 2026, Lindt & Sprüngli confirmed the return of its sold‑out DubaiStyle Chocolate to Canadian shelves, reintroducing the 150g bar and adding a new 40g snackable format crafted with smooth milk chocolate, pistachio filling and kadayif pastry. The launch of a portable 40g DubaiStyle bar alongside the original 150g format highlights how Lindt is using premium, culturally inspired recipes to broaden everyday indulgence occasions. We’ll now examine how expanding DubaiStyle into a new...
SWX:BCHN
SWX:BCHNMachinery

Top 3 European Dividend Stocks Offering Up To 5% Yield

As European markets experience volatility amidst global concerns about AI disruption and economic data releases, the pan-European STOXX Europe 600 Index has managed to reach new highs, reflecting a complex investment landscape. In such an environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate these uncertain times.